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Abstract
Because of weight gain, women often discontinue hormonal contraception, especially depot medroxyprogesterone acetate
(DMPA). Our objective was to conduct a systematic review of studies describing dietary intake or eating behavior in DMPA users
to understand whether the use of DMPA is associated with changes in dietary habits and behaviors leading to weight gain.
We searched the PubMed, POPLINE, CENTRAL Cochrane, Web of Science, and EMBASE databases for reports published
in English between 1980 and 2017 examining dietary intake or eating behavior in healthy women in reproductive age and
adolescents using DMPA (150 mg/mL). Of the 749 publications screened, we excluded 742 due to duplicates (96), not
addressing the key research question (638), not reporting dietary intake data (4), and not evaluating the relationship of body
weight and dietary or eating behaviors (4). We identiﬁed seven relevant studies, including one randomized placebo-controlled
trial, one non-randomized paired clinical trial, and ﬁve cohort studies. The randomized trial found no association and the other
reports were inconsistent. Findings varied from no change in dietary intake or eating behavior with DMPA use to increased
appetite in the ﬁrst six months of DMPA use. Few studies report dietary intake and eating behavior in DMPA users and the
available data are insufﬁcient to conclude whether DMPA use is associated with changes in dietary habits or behavior leading to
weight gain.
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Introduction
One of the most highly effective forms of reversible
contraception is depot medroxyprogesterone acetate
(DMPA). This progestin-only injectable contraceptive is
administered quarterly and works by suppressing ovulation
(1). The failure rate of DMPA birth control is 0.3% in the ﬁrst
year of use when it is used correctly (2). However, more
than 40% discontinue the method in the ﬁrst year (3,4),
mostly due to weight gain (5,6). Several studies have
shown an association between DMPA use and weight
and/or fat mass gain in young women (7–10), although
the mechanism by which DMPA use causes weight gain
is unclear.
There are a number of reports in the medical literature
that seek to identify mechanisms to explain weight gain
in DMPA users (8,11–15). Some studies reported changes
in dietary intake or eating behavior with DMPA use
(7,8,13,16,17). However, after a review of the scientiﬁc
literature, we did not identify a systematic review address-
ing the potential association. The goal of this systematic
review was to summarize studies that address whether
use of DMPA is associated with changes in dietary habits
and eating behaviors leading to weight gain.
Material and Methods
We performed a systematic review of the medical
literature on studies reporting dietary intake or eating
behaviors and the association with weight gain in DMPA
users. Our review followed the guidelines of the PRISMA-
P statement (18). We searched for studies that addressed
our primary research question: "Can DMPA use change
dietary intake or eating behaviors leading to weight gain?"
Search Strategy
We searched PubMed, POPLINE, Cochrane Central
Register of Controlled Trials, SCOPUS, Web of Science,
and EMBASE databases for English-language reports
published between 1980 and 2017. We used the following
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search terms: "dietary intake AND contraception", "caloric
intake AND contraception", "food intake AND contracep-
tion", "dietary intake AND depot medroxyprogesterone
acetate", "caloric intake AND depot medroxyprogesterone
acetate", "food intake AND depot medroxyprogesterone
acetate", "eating behavior AND contraception", and "weight
AND depot medroxyprogesterone acetate". We report our
search strategies in Appendix S1.
Inclusion and exclusion criteria
We reviewed publications describing results assessing
the association of dietary intake or eating behavior and
weight change in healthy women in reproductive-age and
adolescents taking DMPA (150 mg, intramuscular injection).
We included randomized controlled trials and observational
cohort studies (with or without a comparison group),
reporting total calorie intake in percentage, kilocalories,
or grams, assessed with 24-hour food recall or food
frequency questionnaires. In addition, we considered eating
behavior as being self-reported changes in appetite by
means of yes/no questions or validated questionnaires.
We excluded studies that only examined postpartum and
breastfeeding women, systematic reviews, short com-
munications, and studies using DMPA as a treatment for
speciﬁc disorders. We also excluded publications that
did not provide data on dietary intake or eating behavior.
Data collection and analysis
We reviewed all relevant titles and abstracts to
determine whether the reports met our inclusion/exclusion
criteria. One author (P.S.) extracted the data, entered the
information into EndNotes reference manager software,
and conducted the review for duplicate publications.
We reviewed clinical trials and observational studies for
potential biases in the study design, blinding, randomi-
zation method, number of participants, follow-up, compar-
ison group, outcomes, and attempt to control for confounding
factors, following published guidance (19,20).
Results
We identiﬁed 749 publications and excluded 96 articles
because they were duplicates and 638 because the titles
were not consistent with our primary research question.
Additionally, we excluded eight articles because they
did not report dietary intake results even though it was
described in the methodology. In total, seven studies were
eligible for the qualitative analysis (Figure 1). Given the
heterogeneity of the studies, we did not perform a quantita-
tive summary or meta-analysis. Supplementary Table S1
contains a qualitative summary of the seven studies (7,8,11,
13,16,17,21) included in this systematic review.
In terms of study design, six studies (7,8,11,13,16,21)
enrolled U.S. women and one study enrolled Brazilian
women taking DMPA (150 mg intramuscular injection)
as a contraceptive method (17). One report (11) was a
randomized, double-blind, placebo-controlled clinical trial
(RCT), one (17) was a non-randomized clinical trial, and the
other ﬁve (7,8,13,16,21) were observational studies.
Randomized clinical trial
This trial enrolled 20 healthy adult women between 20
and 35 years of age, with 70% classiﬁed as non-Hispanic
White, 5% as Asian or Paciﬁc Islander, 10% as Hispanic,
and 15% as non-Hispanic black; 95% were nulliparous.
The investigators used health-history questionnaires as
criteria for eligibility. They excluded women with eating
disorders or depression. One group (n=10) received a
DMPA injection, and the other group (n=10) received a
saline injection. The study assessed body weight, dietary
intake, and energy expenditure in different phases of the
menstrual cycle. The investigators evaluated diet objec-
tively with a dietary intake scale using three-day records of
consumption of food provided by the research team, and
energy expenditure by indirect calorimetry. They provided
all participants with three meals (breakfast, lunch, and
dinner) and choices of snacks and beverages for three
days, and investigators recorded how much food the
participants consumed. There was no difference between
DMPA users and the placebo group regarding body weight
(P=0.13), caloric intake (P=0.37), and resting energy
expenditure (P=0.76) after the intervention. In both groups,
calorie intake (DMPA: 2390 kcal; placebo group: 2245 kcal)
was higher than daily energy expenditure (DMPA:
1180 kcal/day; placebo group: 1130 kcal/day). The strengths
of this study included the methodology to evaluate dietary
intake, a description of the intervention, randomization, and
outcomes. Limitations included a small sample size and a
short (2 months) follow-up.
Non-randomized clinical trial
The non-randomized clinical trial (17) was performed
with healthy adult Brazilian volunteers. The study assessed
dietary intake and body composition in 28 new DMPA users
compared to 24 new users of the copper intrauterine device
(IUD) matched by body mass index (BMI) and age.
Participants were evaluated during 12 months. Two-thirds
of the women in both groups were non-white. There was no
difference in sociodemographic characteristics, lifestyle
habits, and dietary intake between the groups at baseline.
However, DMPA users had more years of education than
IUD users. To evaluate dietary intake, the researchers used
the 3-day food recall method quarterly providing the mean
quantities of total energy intake, carbohydrates, protein,
and fat. This study assessed body composition by dual
energy X-ray absorptiometry reporting the mean of total
body fat percentage, total body mass, total lean and fat
mass, and central-peripheral fat ratio. The primary outcome
of the study was the signiﬁcant increase of dietary intake in
the DMPA group in up to 12 months of use; however, there
was no association with weight gain. Differences between
the groups included: total energy (Po0.01), carbohydrates
Braz J Med Biol Res | doi: 10.1590/1414-431X20187575
Dietary intake in DMPA users: a systematic review 2/6
(P=0.01), protein (Po0.01), and fat (P=0.01) intake. Regard-
ing body composition, there was an increase in total lean
mass (Po0.04) in the DMPA group. The strengths of this
study included the methodology, duration of follow-up, and
outcomes. Limitations included a small sample size and no
randomization.
Cohort studies
The non-randomized cohort studies (7,8,13,16,21)
included in this review enrolled urban healthy women and
adolescents between 12 and 33 years of age. Exclusion
criteria was eating disorders, contraindication to hormonal
contraception, metabolic disease or use of medications that
could affect weight, breastfeeding, and the use of DMPA
within the past 6 months or use of hormonal contra-
ception (oral contraception, hormonal IUD) within the
past 12 months.
All of the observational cohort studies assessed body
weight and its association with other variables, including
dietary intake and eating behavior, in an attempt to explain
reasons for the weight gain in DMPA users. All ﬁve studies
(7,8,13,16,21) measured body weight objectively and body
composition by dual energy X-ray absorptiometry. Four
cohort studies (7,8,13,21) evaluated dietary intake by
means of 24-hour dietary recall. Two studies (13,21)
showed variance measures (SD) of total energy intake
and macronutrients (carbohydrates, protein, and fat) intake.
One article (16) reported eating behavior by means of a
validated questionnaire - the Three Factor Eating Ques-
tionnaire - without evaluation of dietary intake. Appetite was
evaluated in two studies (7,8) through yes/no questions and
scores (16). The follow-up surveys occurred at 6 (16), 12
(13), and 36 months (7,8,21).
Two studies focused on adolescents (13,16) with a
mean age of 16.2 years. The participants in the remaining
studies (7,8,21) had a mean age of 24.3 years. Two cohort
studies (7,21) included a DMPA group and a non-hormonal
contraceptive group (methods not speciﬁed) as a compar-
ison group. The other three studies (8,13,16) only reported
data from DMPA users. The major strength of the cohort
Figure 1. Flow diagram of study inclusion.
Braz J Med Biol Res | doi: 10.1590/1414-431X20187575
Dietary intake in DMPA users: a systematic review 3/6
studies was the methodology to assess dietary intake
(24-hour dietary recall), and the major limitations were
small sample size or loss to follow-up.
One prospective study (7) evaluated weight, body fat,
and food intake in women between 16 and 33 years old.
Groups included users of combined oral contraceptives
(COC) (n=245), DMPA (n=240), and non-hormonal contra-
ceptives (n=218). The investigators assessed dietary
intake (protein, fat, and carbohydrate) by means of a
24-hour food recall and appetite by means of yes/no
questions. After 36 months of follow-up, weight gain
(+5.1 kg), body fat (+4.1 kg), and body fat percentage
(+3.4%) were higher in DMPA users than in users of
COC or non-hormonal methods (Po0.01). Protein intake
was protective against weight gain and increase in body fat
(Po0.05) among DMPA users. The other dietary variables
and appetite were not associated with changes in body
weight or body composition in DMPA users. Strengths of
this study included a large sample size and a non-hormonal
control group. Limitations included the loss to follow-up of
more than 24% of DMPA users and missing dietary intake
and appetite data (e.g. the number of women that reported
change in appetite and the amount of protein and other
nutrients consumed).
Another prospective study (8) assessed risk factors for
early weight gain (5% gain in the ﬁrst six months of DMPA
use) in 240 women between 16 and 33 years of age
(72 non-Hispanic Black, 82 non-Hispanic White, and 86
Hispanic) who used DMPA. The investigators used 24-hour
food recall to evaluate quantities of protein, fat, and
carbohydrate consumed and they evaluated appetite by
means of yes/no questions. Assessments occurred at
baseline and every 6 months up to 36 months of use.
The investigators noted an association between increased
appetite and early weight gain in the ﬁrst six months of
DMPA use (odds ratio 3.1, 95% conﬁdence interval [CI]
1.5–6.2). However, there was no association between
calorie intake and weight gain at 12 months. The study
had a reasonably large sample size. However, it lacked
a non-hormonal comparison group, had a high loss to
follow-up (24%), and did not report results regarding
macronutrient intake (amount of protein, fat, and carbo-
hydrate consumed).
Le et al. (21) reported a three-year longitudinal follow-up
study of 219 DMPA users, 218 COC users, and 171 users
of non-hormonal contraceptives (type not speciﬁed) between
16 and 33 years old. The researchers evaluated perceived
weight gain by yes/no questions, and dietary intake with
24-hour food recall and reported that women who perceived
a higher weight gain had a higher caloric intake over time
(112 kcal/day, P=0.01). There was no association between
DMPA use and change in food intake (P=0.99). The
strengths of this study were the follow-up and sample size
of DMPA users (more than 200) with hormonal and non-
hormonal comparison groups. Retrospective evaluation of
dietary intake was the principal limitation of this study.
Lange and colleagues (13) assessed weight, BMI
(kg/m2), percentage of body fat mass and lean body
mass, and dietary intake after one year of DMPA use in
adolescents (n=45; mean age=16 years). The research-
ers evaluated dietary intake by 24-hour food recall; the
average caloric intake was 1780 kcal/day (50% from
carbohydrates, 35% from fat, and 13% from protein).
There was no association of total energy intake (P=0.09)
or the consumption of carbohydrates (P=0.15), fat
(P=0.08), or protein (P=0.23) with weight gain in DMPA
users. However, the consumption of ﬁber was inversely
associated with BMI over time (Po0.05). After one year,
the mean BMI and percentage of body fat mass increased,
while lean body mass and food intake decreased.
Strengths of this report include the methodology to
assess dietary intake and report of total energy intake
and macronutrients. The major limitations were the small
sample size (limited statistical power), lack of body
weight data, loss to follow up (31%), and lack of users of
a non-hormonal contraceptive method as a comparison
group.
The prospective study by Bonny et al. (16) assessed
factors associated with weight gain in 43 young new DMPA
users, between 12 and 21 years of age. The researchers
evaluated weight, BMI, body fat percentage, and lean mass
after six months of follow-up. Appetite was measured by
the Three Factor Eating Questionnaire. Percent weight
and body fat increased (+4.2%, P=0.003 and +12.5%,
Po0.001, respectively) in Black adolescents, while appetite
decreased overtime. At six months, appetite score was
higher in Black adolescents than in White adolescents,
but with no association between appetite and weight
change in either. Eating restraint (i.e., prevention of eating)
and eating disinhibition (i.e. continuation of eating) were
predictors of weight gain in Black women. The use of the
Three Factor Eating Questionnaire and objective assess-
ment of changes in weight and body composition were
strengths of this study. Limitations included small sample
size, limited follow-up, users of non-hormonal contra-
ceptive methods as a comparison group, and lack of dietary
intake measures.
Discussion
The articles of this systematic review included two
clinical trial reports and ﬁve prospective observational
studies. Investigators evaluated dietary intake and eating
behavior in DMPA users in an attempt to elucidate the
possible mechanism of the association between DMPA
use and weight variation (7,8,13,16). The RCT found no
difference between DMPA users and the placebo group
regarding body weight, caloric intake, and resting energy
expenditure after the intervention (11). The results of the
non-randomized and cohort studies were variable and
inconsistent. The non-randomized study showed signiﬁ-
cant increase of dietary intake in the DMPA group and no
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association with weight gain (17). Furthermore, one cohort
study reported an association between dietary intake and
weight gain in DMPA users (21), and three studies reported
no association (7,8,13). Eating behavior was a predictor
of weight gain in Black DMPA users in one study (16).
Two studies showed no association between appetite
and weight gain (7,16); however, one of them (8) noted
that appetite was predictive of early weight gain after
6 months of DMPA use.
According to data from the US National Survey of
Family Growth, 6.5% of women between 15 and 34 years
of age chose DMPA as their contraceptive method between
2011 and 2013 (22), with higher rates of DMPA use in
younger women (13.9% of women 15 to 19 years of age;
10.1% of 20 to 24-year-old women) (23). Weight variation
is a common concern in women, and DMPA users state
that weight gain is one of the most common reasons to
discontinue use of the method (5).
The mechanism of weight gain in some DMPA users
is still uncertain. We performed a systematic review in
an attempt to understand whether changes in dietary
habits and behaviors are associated with the observed
weight gain in DMPA users. The principal strength of the
publications was the assessment of dietary intake by
24-hour dietary recall and food frequency records, which
are valid and reliable measures to assess food intake in
adults (24). Additionally, all the cohort studies assessed
weight objectively and used the gold standard technique
(25), dual energy X-ray absorptiometry, to evaluate body
composition.
The principal limitation of the studies was small
sample size (20 women in the RCT, 52 women in the
non-randomized study, and fewer than 60 DMPA users
at last follow-up in the cohort studies). An average of
35–40% of participants were lost to follow-up in the
three studies that reported this measure (7,8,13). One
of the main reasons reported in the studies for the loss
to follow-up was discontinuation of the method. Other
studies have reported similar ﬁndings; for example, it
was reported (4) that more than 50% discontinued DMPA
use in the ﬁrst year. The US-based CHOICE Project
noted that 43% stopped DMPA in the ﬁrst year (3). This is
a major methodological issue with studies addressing
consumption and weight change over time with contra-
ceptive use. We included cohort studies in our review
even though they had some methodological limitations.
The beneﬁts of including observational studies in systema-
tic reviews are the increased generalizability and increased
sample size (26,27).
The goal of this review was to assess studies describ-
ing dietary intake or eating behavior in DMPA users to
elucidate the mechanism of reported weight gain with
DMPA use. To the best of our knowledge, there are no other
reviews in the literature with this objective. A signiﬁcant
limitation of our review was the inability to perform a quantita-
tive summary or meta-analysis of the data due to methodo-
logical differences and heterogeneity of the studies.
Based on our review, we cannot report with conﬁdence
that changes in dietary intake and/or eating behavior are
the key mechanisms to explain weight gain experienced
by DMPA users. Future research should assess dietary
intake and eating behavior as well as metabolic param-
eters and their association with weight change in DMPA
users. For women who experience weight gain with DMPA
use, careful monitoring of diet and exercise are essential.
A healthy lifestyle with a balanced diet that includes con-
sumption of ﬁber (e.g., fruits and vegetables) and appro-
priate caloric intake combined with regular physical activity
for at least 60 min per day are helpful to achieve and
maintain ideal body weight (28–30).
The literature contains few studies reporting dietary
intake and eating behavior in DMPA users. The available
data are insufﬁcient to conclude that changes in dietary
habits or eating behavior are mechanisms leading to weight
gain in DMPA users.
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